TOG 2019 YILI YAYINLAR LİSTESİ

1: Yilmaz MT, Elmali A, Yazici G. Comments on “Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study”. J Oncol Pharm Pract. 2019 Dec;25(8):2060-2062. doi: 10.1177/1078155219858177. Epub 2019 Jun 21. PMID: 31226918.

 

2: Murat Sedef A, Taner Sumbul FKA, Ayberk Besen A, Hacioglu B, Gunaldi M, Nayir E, Tanriverdi O, Arpaci E, Abali H, Ozyilkan O. Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group. J BUON. 2019 Mar-Apr;24(2):650-655. PMID: 31128019.

 

3: Degirmencioglu S, Tanriverdi O, Menekse S, Dogan M, Hacıoglu B, Oktay E, Erdem D, Arpaci E, Uluc BO, Turhal S, Yilmaz M, Pilanci KN, Sakin A, Araz M, Cokmert S, Ozdemir O, Sen E, Nayir E. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG). J BUON. 2019 Jan-Feb;24(1):136-142. PMID: 30941962.

 

4: Araz M, Karaagac M, Korkmaz L, Beypinar I, Uysal M. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group. Curr Probl Cancer. 2019 Aug;43(4):344-353. doi: 10.1016/j.currproblcancer.2018.09.002. Epub 2018 Nov 22. PMID: 30497851.

 

5: Urun Y, Yasar HA, Turna H, Esin E, Sedef AM, Alkan A, Oksuzoglu B, Ozdemir N, Sendur MN, Sezer A, Kılıckap S, Utkan G, Akman T, Akbulut H, Celik I, Abalı H. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. J Oncol Pharm Pract. 2019 Oct;25(7):1658-1664. doi: 10.1177/1078155218805539. Epub 2018 Nov 6. PMID: 30400750.

 

6:  Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. PMID: 30377778.